Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OncoFusion Therapeutics Inc.

oncofusion.com

Latest From OncoFusion Therapeutics Inc.

Deal Watch: Mylan Shareholders Give Thumbs-Up To Perrigo Acquisition

Medivation continues its pipeline expansion efforts beyond Xtandi by paying $410m up front for a Phase III PARP inhibitor from BioMarin. Novo Nordisk acquires a pair of diabetes-focused start-ups, while Immatics will establish a US subsidiary on the MD Anderson Cancer Center campus in Houston.

BioPharmaceutical Deals

Medivation Branches Out With Phase III PARP Inhibitor From BioMarin

Deal is structured with significant upfront cash at $410m, but relatively low earn-out potential for a Phase III cancer candidate. It also gives Medivation two late-stage oncology compounds beyond Xtandi; CEO David Hung outlines strategy.

BioPharmaceutical United States

Deals Shaping The Medical Industry, June 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.

BioPharmaceutical Consumer
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OncoFusion Therapeutics Inc.
  • Senior Management
  • Shaomeng Wang, PhD, CSO
    Brian Wood, Dir., Bus. Dev.
  • Contact Info
  • OncoFusion Therapeutics Inc.
    1600 Huron Pkwy., 2nd Fl
    Univ. of MI
    Ann Arbor, MI 48109
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register